Drug Profile
REGN 846
Alternative Names: R846; REGN846; SAR 302532Latest Information Update: 22 Aug 2013
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals; sanofi-aventis
- Developer Regeneron Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis
Most Recent Events
- 06 Aug 2013 Discontinued - Phase-I for Atopic dermatitis in Australia (IV)
- 06 Aug 2013 Discontinued - Phase-I/II for Atopic dermatitis in Finland , Germany and Poland (IV)
- 06 Aug 2013 Discontinued - Phase-II for Atopic dermatitis (IV)